With $15 million in funding, OSI and the broader osteosarcoma community, pediatric cancer foundations, and Break Through Cancer (BTC) have teamed up to bring BTC’s team-based approach to osteosarcoma, bringing together investigators from across the country and around the world.
Supported by the Osteosarcoma Institute and Ethos Discovery, the MIMIC trial evaluates a new method of removing lung metastases in dogs, providing insights that can directly inform human osteosarcoma treatment and drug development.
The U.S. Food and Drug Administration (FDA), the Osteosarcoma Institute (OSI), and others are coming together to shape the future of osteosarcoma clinical trials.
Veterinary oncologist Chand Khanna, DVM, PhD, explains how osteosarcoma in dogs is helping researchers unlock new possibilities for treating human patients.
